Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns...(insomnia with more than 90% of current i...)

The headline results of the first Phase II study with EVT 201 were very positive in terms of all aspects of the problems faced by insomniacs, i.e. sleep onset and sleep maintenance and yet the patients didn't feel any drug hang-over effects after waking in the morning. Furthermore, in two previous Phase I/II proof-of-principle studies in subjects with induced insomnia, EVT 201 significantly reduced Wake After Sleep Onset (WASO) while significantly increasing the Total Sleep Time (TST) and quality of sleep with no subjective residual effects. The studies were conducted in a sleep laboratory setting using the traffic noise model of insomnia in healthy male volunteers. In this setting an average of 52 decibels of recorded traffic noise is played throughout the night thereby provoking insomnia. This model has been used to evaluate several insomnia treatments currently in development and on the market. EVT 201 showed no tolerance/dependence liabilities in pre-clinical studies and no interaction with alcohol.

Joern Aldag

President & Chief Executive Office

T: +49-(0)40-560-81-242

F: +49-(0)40-560-81-333

joern.aldag@evotec.com

Anne Hennecke

Senior Vice President

Investor Relations & Corporate Communications

T: +49-(0)40-560-81-286

F: +49-(0)40-560-81-333

anne.hennecke@evotec.com

Evotec AG (Headquarters)

Schnackenburgallee 114

22525 Hamburg, Germany